XFOR
X4 Pharmaceuticals Inc
2.90$
+2.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -100.0% | – | -0.5% | +156.1% | +1,908.9% | -93.2% | -10.5% | +45.5% | +5.5% | +225.2% | – | |
| – | -87.6% | +0.0% | +645.2% | -33.5% | -1.6% | +1,557.3% | -90.1% | -24.3% | +3.5% | +54.5% | +170.4% | – | |
| – | – | – | – | +150.5% | +347.4% | +2,002.7% | -93.8% | -5.9% | +56.8% | -3.3% | +240.7% | – | |
| – | -18.1% | +30.1% | +4.7% | -7.9% | +13.7% | -16.0% | -0.2% | -4.8% | +6.8% | -16.5% | -2.4% | – | |
| – | +22.1% | +75.6% | -23.8% | +17.9% | -3.3% | -0.8% | -36.6% | +21.6% | +275.6% | -84.0% | +22.0% | – | |
| – | -5.9% | +48.1% | -8.7% | +2.2% | +6.0% | -9.8% | -16.6% | +4.3% | -10.4% | -13.4% | +5.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +15.4% | -0.6% | +16.1% | +10.9% | -4.6% | -4.5% | +1.4% | +1.1% | -3.1% | -2.4% | +1.4% | – | |
| – | – | – | – | -140.4% | – | – | -8,234.2% | – | – | – | – | – | |
| – | +26.9% | -42.4% | -5.3% | -16.7% | +1,620.0% | -86.8% | +8.8% | -181.1% | – | – | – | – | |
| – | – | – | – | -140.4% | – | – | -9,228.0% | – | – | – | – | – | |
| – | – | – | – | -136.5% | – | – | -868.6% | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.